Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anteris Technologies GlobalASX:AVR +3.04%45 3-Year EBITDA Growth Rate is -5.80% as of Mar. 2026. GuruFocus rates ASX:AVR with a GF Score™ of 45/100. The stock has 5 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Anteris Technologies Global ranks worse than 73.08% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -5.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -12.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 10.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Anteris Technologies Global was 62.70% per year. The lowest was -64.10% per year. And the median was -5.30% per year.
Anteris Technologies Global (ASX:AVR) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Anteris Technologies Global 3-Year EBITDA Growth Rate Related Terms
ASX:AVR vs BVS, SIBN, INMD: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Anteris Technologies Global's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anteris Technologies Global 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Anteris Technologies Global's 3-Year EBITDA Growth Rate falls into.
Anteris Technologies Global 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -5.80% mean?
Anteris Technologies Global (ASX:AVR) has a 3-Year EBITDA Growth Rate of -5.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Anteris Technologies Global and its competitors. According to the industry distribution chart, Anteris Technologies Global ranks #505 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 73.1%.
Is Anteris Technologies Global's 3-Year EBITDA Growth Rate too high?
Anteris Technologies Global's current 3-Year EBITDA Growth Rate is -5.80%. Based on the distribution chart, Anteris Technologies Global ranks #505 out of 691 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Anteris Technologies Global has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's 3-Year EBITDA Growth Rate compare to BVS and SIBN?
According to the Medical Devices & Instruments industry distribution chart, Anteris Technologies Global ranks #505 out of 691 companies for 3-Year EBITDA Growth Rate. This places Anteris Technologies Global in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Anteris Technologies Global and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anteris Technologies Global's current 3-Year EBITDA Growth Rate is -5.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (ASX:AVR) has a current 3-Year EBITDA Growth Rate of -5.80%. The current 3-Year EBITDA Growth Rate is -5.80%. Anteris Technologies Global's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Anteris Technologies Global (ASX:AVR), the current 3-Year EBITDA Growth Rate is -5.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
45GF Score
Get the complete analysis for ASX:AVR
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVR has been successfully added to your 
